63 completed, 19 unknown, 16 terminated, 8 withdrawn. 119 Phase 3, 14 Phase 2.
Follow Head and Neck Cancer: new trials by email Literature Review of Head and Neck Cancer trials Research Report on Head and Neck Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck Cancer Standard of Care (SOC), Experimental drug - Head and Neck Cancer | Phase 3 | Not yet recruiting | University Health Network, Toronto | 288 | 2026-11-01 | 2026-10-20 |
| APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma APG-157, Surgery, Radiation/Chemotherapy - Head and Neck Cancer, Head and Neck (HNSCC) | Phase 3 | Not yet recruiting | Aveta Biomics, Inc. | 826 | 2026-07-01 | 2026-07-01 |
| Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy Nurse-led preemptive symptom management, Concentional care - Head and Neck Cancer | Phase 3 | Recruiting | West China Hospital | 170 | 2026-03-15 | 2026-04-01 |
| Trop2-targeted immunoPET Imaging of Solid Tumors [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4 - Solid Tumor, Solid Carcinoma | Phase 2 / Phase 3 | Recruiting | RenJi Hospital | 400 | 2024-12-23 | 2026-05-29 |
| A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's IMRT - adjuvant concurrent CRT/ RT, ommission of IMRT - adjuvant concurrent CRT/ RT for regional lymphatics, Cisplatin - Head and Neck Cancer | Phase 2 / Phase 3 | Recruiting | All India Institute of Medical Sciences | 396 | 2024-04-03 | 2026-05-06 |
| Optimising Patient Experience in Head and Neck Radiotherapy Conventional 5 point closed face immobilisation mask., 5 point open face immobilization mask, 3 point open face immobilization mask - Head and Neck Cancer | Phase 3 | Unknown | Irish Research Radiation Oncology Group | 201 | 2024-01-02 | 2024-03-25 |
| Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) Xevinapant, IMRT, Placebo - Head and Neck Cancer | Phase 3 | Terminated | EMD Serono Research & Development Institute, Inc. | 166 | 2022-10-06 | 2026-02-19 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO Reduced dose intensity of IO - Lung Cancer Metastatic, Renal Cell Carcinoma | Phase 3 | Active not recruiting | UNICANCER | 646 | 2022-03-08 | 2026-07-17 |
| Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy Miraculin, Miracle Fruit Placebo Cube - Head and Neck Cancer, Taste Dysfunction | Phase 3 | Active not recruiting | University of California, San Francisco | 40 | 2022-03-04 | 2026-08-11 |
| Tumescence in HNC Skin Graft Reconstruction Tumescence During STSG Harvest - Head and Neck Cancer, Surgery--Complications | Phase 3 | Active not recruiting | University of California, Davis | 58 | 2021-09-01 | 2026-02-18 |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC Buparlisib & Paclitaxel - Head and Neck Cancer | Phase 3 | Completed | Adlai Nortye Biopharma Co., Ltd. | 487 | 2020-12-12 | 2025-11-17 |
| Clinical Study On Acute Radiotherapy-Induced Oral Mucositis In Patients With Locally Advanced Head And Neck Tumors Jeksung combined with anti-radiation spray - Head and Neck Cancer | Phase 3 | Completed | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | 100 | 2020-08-17 | 2023-04-24 |
| Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer SABR boost and de-escalated chemoradiation, Standard chemoradiation - Head and Neck Cancer, Oropharynx Cancer | Phase 3 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 360 | 2020-02-23 | 2026-08-24 |
| Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck enoblituzumab, MGA012, MGD013 - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 2 / Phase 3 | Withdrawn | MacroGenics | 2019-10-01 | 2022-02-08 | |
| Multimodality- Adapted Dose Modification in Head and Neck Cancer Radiation Therapy  Dose escalation, Standard dose - Head and Neck Cancer | Phase 2 / Phase 3 | Unknown | National Cancer Institute, Egypt | 75 | 2019-09-16 | 2021-06-21 |
| ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy ASP-1929 Photoimmunotherapy, Physician's Choice SOC - Head and Neck Cancer | Phase 3 | Active not recruiting | Rakuten Medical, Inc. | 135 | 2019-05-09 | 2025-01-16 |
| Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy - Hepatocarcinoma, Lung Cancer | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 200 | 2018-11-01 | 2024-06-25 |
| Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy Surgical resection of primary tumor, Adjuvant radio(-chemo)therapy, Neoadjuvant Nivolumab - Head and Neck Cancer | Phase 3 | Unknown | Universitätsklinikum Hamburg-Eppendorf | 276 | 2018-08-21 | 2023-05-23 |
| An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck Nivolumab, BMS-986205, Cetuximab - Head and Neck Cancer | Phase 3 | Withdrawn | Bristol-Myers Squibb | 2018-03-28 | 2019-04-18 | |
| Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) Nivolumab, Epacadostat, Placebo - Head and Neck Cancer | Phase 3 | Withdrawn | Incyte Corporation | 2017-12-15 | 2019-12-20 |
Showing 20 of 119. Sign in to see all of them.
Head and Neck Neoplasms (119) · Squamous Cell Carcinoma of Head and Neck (57) · Radiation Injuries (10) · Salivary Gland Neoplasms (9) · Tongue Neoplasms (9) · Esthesioneuroblastoma, Olfactory (7) · Carcinoma, Squamous Cell (6) · Mouth Neoplasms (6) · Mucositis (6) · Neoplasms (6) · Oropharyngeal Neoplasms (6) · Pain (6) · Stomatitis (6) · Xerostomia (6) · Laryngeal Neoplasms (4)
Neoplasms by Site (119) · Neoplasms (113) · Neoplasms by Histologic Type (69) · Neoplasms, Glandular and Epithelial (69) · Carcinoma (64) · Carcinoma, Squamous Cell (57) · Stomatognathic Diseases (34) · Mouth Diseases (32) · Mouth Neoplasms (14) · Pathological Conditions, Signs and Symptoms (14) · Salivary Gland Diseases (14) · Otorhinolaryngologic Diseases (13) · Respiratory Tract Diseases (11) · Wounds and Injuries (11) · Digestive System Diseases (10)
Cisplatin (35) · Radiotherapy (29) · Fluorouracil (19) · Cetuximab (11) · Carboplatin (8) · Radiotherapy, Intensity-Modulated (7) · Chemotherapy, Adjuvant (6) · Paclitaxel (6) · Docetaxel (5) · Drug Therapy (5) · Radiation (4) · Standard of Care (4) · Fibroblast Growth Factor 7 (3) · Nivolumab (3) · Pilocarpine (3)
Radiation Therapy Oncology Group (15) · Alliance for Clinical Trials in Oncology (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Eastern Cooperative Oncology Group (4) · Bristol-Myers Squibb (3) · National Cancer Centre, Singapore (3) · All India Institute of Medical Sciences (2) · European Institute of Oncology (2) · Incyte Corporation (2) · M.D. Anderson Cancer Center (2) · NCIC Clinical Trials Group (2) · Royal Marsden NHS Foundation Trust (2) · SWOG Cancer Research Network (2) · UNICANCER (2) · Adlai Nortye Biopharma Co., Ltd. (1)
United States (50) · Canada (23) · France (19) · United Kingdom (19) · Spain (12) · Italy (11) · Belgium (10) · Germany (10) · China (9) · Poland (9) · Netherlands (8) · Switzerland (8) · Hungary (7) · India (6) · Japan (6)
Andy M. Trotti, MD (2) · Chris Nutting (2) · David J. Adelstein, MD (2) · Francis G. LeVeque, DDS (2) · Jacques Bernier, MD, PhD (2) · Mitchell Machtay, MD (2) · Phuc Felix Nguyen-Tan, MD (2) · Robert C. Miller, MD (2) · Aminah Jatoi, MD (1) · Anna Sureda (1) · Arlene A. Forastiere, MD (1) · Arnold M. Markoe, MD, ScD (1)
PMID 31420360, PMID 41343184, PMID 30548235, PMID 10924966, PMID 11560968, PMID 12499279, PMID 12525193, PMID 12788192, PMID 14508838, PMID 14529772, PMID 14645636, PMID 15128893, PMID 15128894, PMID 15452834, PMID 15534360, PMID 15908667, PMID 15936546, PMID 16012523, PMID 16161069, PMID 16287132, PMID 16314626, PMID 16376489, PMID 16467544, PMID 16648511, PMID 16724649, PMID 16782926, PMID 17293228, PMID 17394940, PMID 17716826, PMID 17762442, PMID 17960012, PMID 18784101, PMID 18805649, PMID 19107946, PMID 19156911, PMID 19176454, PMID 19332518, PMID 19596158, PMID 19667273, PMID 19875337, PMID 19897418, PMID 20335368, PMID 20382075, PMID 20406930, PMID 20530316, PMID 20842129, PMID 21236730, PMID 21300466, PMID 21357786, PMID 21377930
2005 (2), 2017 (2), 2016 (1), 2023 (1), P30CA006516 (1), P30CA008748 (1), P30CA016042 (1), R01CA107080 (1), R01CA148707 (1), R21CA098792 (1), U10CA032102 (1), U10CA037404 (1), U10CA037429 (1), U10CA180868 (1)